BioCentury | Aug 3, 2020

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...
BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Vesicular trafficking protein fusion targets for metastatic osteosarcoma

DISEASE CATEGORY: Cancer INDICATION: Bone cancer Interrupting the interaction between RAP1GDS1, which can regulate cell migration, and vesicle trafficking protein RAB22A fusions could treat metastatic osteosarcoma bearing the mutations. The RAB22A fusion proteins are caused...
BioCentury | Jul 13, 2020

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | May 28, 2020
Distillery Therapeutics

Increasing WWTR1 degradation for NASH

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting proteasomal degradation of the transcription factor WWTR1 by inhibiting a cholesterol-associated signaling pathway could treat NASH. The cholesterol trafficking proteins GRAMD1B and GRAMD1C activate SAC, which in...
BioCentury | May 9, 2020

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

Fortress Biotech broke from its mold of licensing clinical assets to access a Columbia University peptide nucleic acid technology in discovery. The new technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

Deploying its HPV serology testing lab to validate COVID-19 assays is one of three ways NIH’s National Cancer Institute is retooling cancer research activities to take on the pandemic. In a virtual advisory committee meeting...
BioCentury | Apr 9, 2020

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally signal that an IPO is in the offing, President and CEO Barbara Weber thinks the wealth of targets that...
Items per page:
1 - 10 of 1167